Published in J Thorac Oncol on October 26, 2016
MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition. PLoS One (2017) 0.75
Circulating Tumor DNA Identifies EGFR Co-Amplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. J Thorac Oncol (2017) 0.75
Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer. Front Oncol (2017) 0.75
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 11.68
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
Chromosome aberrations in solid tumors. Nat Genet (2003) 7.01
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov (2008) 4.76
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn (2015) 3.84
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol (2009) 3.57
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res (2006) 3.12
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med (2015) 2.88
Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol (2001) 2.72
ALK in lung cancer: past, present, and future. J Clin Oncol (2013) 2.70
A role for common fragile site induction in amplification of human oncogenes. Cancer Cell (2002) 2.63
The landscape of kinase fusions in cancer. Nat Commun (2014) 2.48
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell (2001) 2.26
Anchored multiplex PCR for targeted next-generation sequencing. Nat Med (2014) 2.25
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. Clin Cancer Res (2016) 2.19
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03
An overview of the c-MET signaling pathway. Ther Adv Med Oncol (2011) 1.95
The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell (2004) 1.93
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov (2015) 1.91
Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol (2009) 1.81
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog (2008) 1.68
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov (2015) 1.67
Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res (1996) 1.57
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res (2013) 1.52
Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci (2008) 1.31
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol (2016) 1.27
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. J Clin Oncol (2015) 1.26
High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol (2012) 1.26
The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization. Gene (1998) 1.15
Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas. Am J Pathol (2010) 1.12
Targeting MET Amplification as a New Oncogenic Driver. Cancers (Basel) (2014) 1.11
The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg (1998) 1.09
MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res (2006) 1.09
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol (2015) 1.07
c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol (2012) 1.06
Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress. J Med Chem (2013) 1.01
Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer (2011) 1.00
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer (2015) 0.98
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation. Clin Lung Cancer (2015) 0.93
Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. Hum Pathol (2001) 0.92
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol (2015) 0.84
Gene of the month: MET. J Clin Pathol (2015) 0.82
MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor. J Thorac Oncol (2015) 0.82
The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models. Cancers (Basel) (2014) 0.82
Prognostic and predictive value of MET deregulation in non-small cell lung cancer. Ann Transl Med (2015) 0.81
MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis. PLoS One (2014) 0.81
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol (2016) 0.80
A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib. Invest New Drugs (2016) 0.77
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. J Thorac Oncol (2016) 0.76
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov (2014) 1.88
Therapy of Small-cell Lung Cancer (SCLC) With a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. Clin Cancer Res (2017) 0.75